CD274 and neoplasm: In the subsequent studies, the development of targeted drugs that specifically inhibit DHHC3/9 could be considered to achieve specific modulation of PD-L1 palmitoylation, and targeting PD-L1 palmitoylation could increase the sensitivity of tumor cells toward T-cell-mediated killing and retard tumor growth.